Physician profile

Angela Argento

Pulmonary Disease · Baltimore, MD

NPI 1518115526

$268,819.00

in general payments reported to CMS, 2019-2025

32 companies · $71K in 2025

The $71K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$109,981.25
Consulting Fee$51,582.75
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$15,120.00
Travel and Lodging$10,706.70
Food and Beverage$9,859.72
Honoraria$1,000.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Olympus Corporation of The Americas $136,739.85 2020-2025 Single Use Suction Valve (Sterile), Eves Eus Ultrasound Bronchofibervideoscope, Vizishot 2 Flex
Cook Incorporated $25,113.75 2019-2025
Olympus America INC. $16,414.54 2019-2025 Evis Exera III Bronchovideoscope, Probe Driving Unit, Single-Use Flexible Video Bronchoscope
Boston Scientific Corporation $15,985.05 2019-2023
Bard Peripheral Vascular, INC. $11,801.32 2023-2025 Pleurx
Intuitive Surgical, INC. $9,876.66 2019-2024 Da Vinci Surgical System
Coaptech, INC. $9,850.10 2024-2025 Puma System, Puma System
Olympus Corporation $7,577.67 2021-2023
Merck Sharp & Dohme LLC $6,252.20 2023
Astrazeneca Pharmaceuticals LP $6,001.21 2021-2025 Tagrisso, Imfinzi
Pinnacle Biologics, INC $4,915.54 2023 Photofrin
Erbe USA INC $3,124.79 2019-2025 Erbe Vio Apc Cryo, Vio/Cryo/Apc, Vio Cryo Apc
Daiichi Sankyo INC. $2,416.50 2025 Enhertu
Pulmonx Corporation $2,207.52 2019-2023 Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve
Covidien LP $1,747.05 2019-2020
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Ambu INC. $1,670.63 2020-2024
Ethicon INC. $1,466.95 2019-2023 Monarch Platform
Olympus Medical Systems Corporation $1,100.00 2024
Veran Medical Technologies, INC. $829.29 2021-2023 Spin Vision Video Processor
Merit Medical Systems INC $700.00 2025 Through The Scope
Cook Medical LLC $533.23 2019-2023 Wayne
Medtronic, INC. $494.24 2022-2024 Arcpoint, Illumisite
Gyrus Acmi, INC. $440.00 2024 Spiration Valve System
Spiration, INC. $440.00 2019
Becton, Dickinson and Company $351.29 2019-2025 Pleurx
Auris Health, INC. $238.08 2019
Conmed Corporation $144.77 2021
Siemens Medical Solutions USA, INC. $124.91 2025
Bard Access Systems, INC. $113.78 2019
Steris Corporation $89.04 2025
Getinge USA Sales, LLC $54.72 2025 Base Unit Servo-U
Body Vision Medical INC. $4.32 2023 Lungvision

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Angela Argento

$268,819.00

in general payments reported 2019-2025

Years
2019-2025
Top company
Olympus Corporation of The Americas
Context
The $71K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/833129/angela-argento

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.